Last reviewed 2026-04-20 · How we verify

Calcium Acetate (CALCIUM)

Calcium Acetate works by providing supplemental calcium to the body, which is essential for various bodily functions including muscle and nerve function.

Calcium Acetate is a small molecule medication developed by Fresenius Kabi USA and currently owned by Fresenius Medical Care. It was FDA-approved in 2022 for the treatment of end-stage renal disease. The commercial status of Calcium Acetate is generic, with 13 generic manufacturers available. Key safety considerations include monitoring of serum calcium levels and potential interactions with other medications. Calcium Acetate is used to manage low calcium levels in patients with end-stage renal disease.

At a glance

Mechanism of action

Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.

Approved indications

• end stage renal disease
• end stage renal disease

Common side effects

• Hypercalcemia
• Nausea
• Vomiting
• Pruritus
• Dizziness
• Edema
• Weakness

Drug interactions

• Tetracyclines
• Fluoroquinolones
• Ciprofloxacin
• Anti-arrhythmic medications
• Anti-seizure medications

Key clinical trials

• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
• A Study of Auxora in Patients With Severe COVID-19 Pneumonia (PHASE2)
• Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (PHASE2)
• Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
• Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1,PHASE2)
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
• A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (PHASE3)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.